You are here

Share:

Ratio Based Biomarkers for the Prediction of Cancer Survival

Summary
The NCI seeks licensees or co-development partners for this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer.
NIH Reference Number
E-025-2009
Product Type
Keywords
  • AKT pathway, diagnostic, prognostic, extrahepatic cholangiocarcinoma
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

The AKT pathway plays a key role in the regulation of cellular survival, apoptosis, and protein translation and has been shown to have prognostic significance in a number of cancers.  Recently, the inventors have identified several functions of the AKT pathway in certain cancers, such as extrahepatic cholangiocarcinoma (EHCC).

The NCI seeks partners to license or co-develop this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer.  Utilizing multiplex tissue immunoblotting, the inventors have demonstrated that PTEN expression, PTEN/p-AKT ratios, and PTEN/p-mTOR ratios can predict the survival of cancer patients.  These biomarkers may provide useful diagnostic information for cancer patients as well as identify patients appropriate for mTOR analog-based chemotherapy or agents directed against AKT.

Potential Commercial Applications
  • Diagnostic and Prognostic tool to detect the presence of cancer and predict the relative cancer survival rate for a subject with cancer
  • Method of identifying patients appropriate for therapies targeted to the AKT pathway
  • A kit for detecting cancer associated proteins in a sample
Competitive Advantages
  • Useful to predict cancer patient survival
Inventor(s)

Stephen M. Hewitt (NCI), Joon-Yong Chung (NCI)

Development Stage
Publications

Chung J, et al. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. [PMID 19147772]

Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 61/114,501, Filed 14 Jan 2009
Therapeutic Area
Updated
Thursday, March 29, 2018